

## Nocardia in Spinal Epidural Abscess: A Surprise Guest



### Medical Science

KEYWORDS :

**Vinayak I kadlimatti**

Assistant Professor Dept Of Neurosurgery JSS Hospital Mysore.

**Madhuri Kulkarni**

Professor & HOD, Dept Of Microbiology, JSS Hospital Mysore.

**K.V Shivanand Reddy**

Post Graduate Dept of General Surgery, JSS Hospital Mysore.

#### Introduction

Spinal epidural abscess (SEA) is a rare neurosurgical emergency condition which accounts for 2.5 – 3 cases per 10 000 hospital admissions per year<sup>1</sup>. Early diagnosis and treatment has better outcome. Delayed diagnosis or inadequate treatment results in long term severe or disabling neurological deficits. The reason for recent rise in incidence of spinal epidural abscess includes, the growth of elderly population, multiple chronic medical conditions, intravenous drug abuse, indwelling intravenous catheters, increase in transplant recipients and use of immunosuppressive drugs. Spinal epidural abscess is primarily a bacterial infection, *Staphylococcus aureus* being the most common causative agent. Other organisms such as *Staphylococcus epidermidis*, *Streptococcus viridians*, *Streptococcus pneumoniae*, *E. faecalis*, *Propionibacterium* and Gram negative organisms such as *Escherichia coli*, *Pseudomonas*, *Salmonella*, *Enterobacter*, *Klebsiella*, *Haemophilus*, *Proteus* also cause SEA<sup>2</sup>. Nocardiosis of CNS is a very rare. *Nocardia* is a Gram positive aerobic actinomycete which belongs to the genus *Nocardia*. Infection by this organism usually occurs in patients with impaired immunity. Improvement in recent diagnostic techniques has helped in isolation of the organism more frequently. Magnetic resonance imaging (MRI) has markedly enhanced the ability to detect these conditions, allowing earlier diagnosis, thereby avoiding complications.

#### CASE REPORT

A 22 year old male patient was admitted to our hospital with chief complaints of fever, cough and breathlessness of 2 weeks duration. Patient was a known case of nephrotic syndrome since 5 years and was on regular treatment with steroids. He was diagnosed to have bilateral pleural effusion. Pleural fluid was drained and was sent for microbiological analysis. Gram stain was reported as containing plenty of inflammatory cells but cultures did not yield any growth and patient was treated medically.

At the time of admission patients general condition was good with vitals being stable and power of all the four limbs was 5/5. Patient had Cushingoid facial features, with both lower limb oedema. Respiratory system examination revealed bilateral decreased breath sounds.

Pulmonologist and nephrologist consultation was sought with regard to bilateral pleural effusion and nephrotic syndrome. Right side Intercostal drain was inserted and pleural fluid was sent for microbiological analysis and was reported as containing plenty of inflammatory cells but cultures did not yield any growth. With all this, diagnosis of Nephrotic syndrome with bilateral pleural effusion with empyema of right lower lobe with Cushing's syndrome due to chronic steroid use was made.


Patient gradually developed weakness of both lower limbs with power of the limbs being 2/5 for which neurosurgery consultation was sought. MRI revealed cervico-dorsal tracking down of exudative fluid from the pleural space into the fascial planes posteriorly and also into the diaphragmatic recess and into the cord canal from D 6 to D 12 approximately 10 cm fluid quantity about 450 ml. Patient was advised surgery and evacuation of the abscess. Pa-

tient deteriorated rapidly in his neurological condition (lower limb power 0/5). Patient underwent D6 to D12 decompressive laminectomy with evacuation of the abscess. Pus was sent for microscopy, culture and sensitivity. Gram stain of the sample revealed plenty of inflammatory cells with plenty of Gram positive, branching filamentous bacteria. They were partially acid fast on staining by modified Ziehl Neelsen's technique. Culture on Blood agar, Saborauds dextrose agar and Lowenstein medium yielded dry, chalky white colonies after 24 hours incubation. The organism was identified as *Nocardia asteroides* by biochemical tests. The isolate was sensitive to ampicillin, erythromycin, ceftriaxone, cotrimaxazole, amikacin and imipenem. Other laboratory parameters included erythrocyte sedimentation rate (ESR) of 55 mm per hour, and white blood cell count of 15,600 cell/cmm. Two sets of blood cultures remained sterile after 2 weeks incubation.



**Fig 1 : Epidural abscess from D6 to D 12.**

The patient improved dramatically after the initial irrigation and debridement, eliminating the need for subsequent procedures. He was started on ceftriaxone and metronidazole. After the preliminary report of *Nocardia* species was received, antibiotic treatment was changed to cotrimaxazole, Amikacin and linezolid. *Nocardia asteroides* was confirmed via the final report. The patient was continued on antibiotics while in the hospital and on discharge. He had an unremarkable course on discharge with both lower limbs power 2/5.



Modified ZN staining showed branching Acid fast bacilli



**Blood agar- chalky white dry colonies**



**LJ media- yellow pigmented colonies**

## DISCUSSION

*Nocardia* is a rare cause of neuroinfection, usually only affecting immunocompromised patients. It is most commonly found in soil, decaying vegetable matter, and aquatic environments. This infection is typically transmitted via inhalation of dust particles or direct contact penetrating past the natural human protective barriers. The most common species to cause infection is one of the variants of the *N. asteroides* complex, which consists of *N. asteroides sensu stricto*, *N. farcinica*, and *Nocardia nova*<sup>3</sup>. The 3 main types of disease caused by *Nocardia* (nocardiosis) are cutaneous disease, pulmonary disease, and disseminated disease. *Nocardia farcinica* is the most virulent form and is more frequently found to cause disseminated disease<sup>4</sup>.

Disseminated disease is also more prevalent in immunocompromised patients. *Nocardia brasiliensis* is the most common to cause cutaneous disease, often leading to the development of a mycetoma over months to years. The presentation in our patient is unknown (3,4,5). The patient's only recollection of a potential source was an epidural pain block that he received approximately 2 months prior to identification of the abscess. When a patient presents with back pain, a spinal epidural abscess is a rare cause and not likely to be in the initial differential diagnosis. An indicator that an abscess could be present is when a patient presents with the classic triad of fever, spinal pain, and neurologic deficit. Fever often leads clinicians to include a spinal epidural abscess in the differential diagnosis because it is typically absent in the more common presentations of back pain. Once a spinal epidural abscess is determined as the cause, the aetiological

agents in order of likelihood range from *Staphylococcus aureus* (approximately two-thirds of the total cases), Gram negative bacilli, streptococci, coagulase negative staphylococci (mostly in patients with previous spinal instrumentation), and anaerobes. *Nocardia* is another potential cause of epidural abscess. The likelihood of infection with this type of bacteria is minimal but should be considered. Increased concerns for nocardiosis typically involves patients with depressed cellular immunity or humorally immunocompromised patients, such as those with acquired immune deficiency syndrome, hematologic and solid organ malignancies, prolonged systemic steroid therapy, and transplant recipients<sup>5</sup>. However, immunocompetent individuals are still capable of developing an infection.

The overall incidence of nocardiosis is often not reported in literature, with the most frequently cited study in the United States reporting 500 to 1000 new cases per year between 1972 and 1974. (10) These numbers have likely increased since then due to the increase in immunocompromised individuals and likely lack reporting in the initial count because it is not a reportable disease. Although the incidence is limited, it should remain in the differential diagnosis, especially when cultures are still negative after a few days and the clinical suspicion of infection is high. It is difficult to diagnose *Nocardia* because of its long incubation period<sup>6</sup>. The typical time frame for growth can be as early as 4 days, but it can take several weeks for the colonies to develop. In our case, it took 2 days for the colonies to grow, with a final report after 8 days for speciation of the isolate. Correspondence with the laboratory is vital when *Nocardia* is being considered to ensure that cultures are kept long enough to allow for ample growth periods<sup>6</sup>. *Nocardia* is grown in the laboratory using common fungal (ie, Sabouraud dextrose agar) or mycobacterial isolation media (ie, Middlebrook synthetic agar and Lowenstein-Jensen medium). Selective media, such as Thayer-Martin agar, can be used to increase the yield. The stains that are used to differentiate *Nocardia* from *Actinomyces* are the Kinyoun acidfast stain or a Ziehl-Neelsen acid-fast stain(1). The Lysozyme test can also be used to identify *Nocardia* species that is beneficial for those species which are not acid fast. *Nocardia* is identified as weakly acid-fast positive vs its counterpart, *Actinomyces*, which is an acid-fast negative<sup>7</sup>. The property that causes the differentiation of *Nocardia* is the varying amounts of mycolic acid within its cell wall causing the acid-fast staining. Antibiotics are the treatment of choice, except when surgery is initially indicated, with antibiotics still given postoperatively. Sulfonamides have been the preferred antibiotic used for treatment for many years. Due to resistance developing to sulfonamides in many variants of *Nocardia*, a combination therapy is often given, especially in severe or disseminated disease. To ensure coverage of all isolates of *Nocardia* in severe cases, a 3-drug regimen of trimethoprim-sulfamethoxazole, amikacin, and either ceftriaxone or imipenem should be started because no resistance has been reported to this combination(4-5). In milder cases, treatment with trimethoprim-sulfamethoxazole, minocycline, or ceftriaxone have shown to be effective. Treatment with trimethoprim sulfamethoxazole in combination with a fluoroquinolone has also been effective, but only in mild cases. *Nocardia farcinica* is the 1 type of *Nocardia* that should be of concern when treating empirically with a fluoroquinolone because most patients are resistant to it. (7) *Nocardia farcinica* has also shown resistance to third-generation cephalosporins. Linezolid has demonstrated effective in vitro activity against most species and strains, but clinical data are limited(9).

It has promising results as a potential option in the replacement of the current treatment regimens when resistance is a concern. Once sensitivities are obtained, the focus of the treatment should be narrowed appropriately. Intravenous therapy treatment must be continued for several weeks with an eventual transition to oral therapy. Duration of treatment is dependent on

type of disease and organ involvement. Spinal epidural abscess due to *Nocardia* is an extremely rare condition, and a high index of suspicion, prompt collection and microbiological analysis of the exudate is warranted for accurate diagnosis. Treatment involving a combination of surgical debridement and prolonged sulphonamide administration comes in as the mainstay of managing these patients. When treating patients with a possible spine infection, one should include *Nocardia* in the differential diagnosis.

## REFERENCE

1. P. Sendi t. Bregenzer and w. Zimmerli Spinal epidural abscess in clinical practice q j med 2008; 101:1–12. Youmans text book. | | 2. Farida Hammad,<sup>1\*</sup> Barbara Vidal, Youcef Douadi et al. *Nocardia nova* as the Causative Agent in Spondylodiscitis and Psoas Abscess. JOURNAL OF CLINICAL MICROBIOLOGY, Jan. 2007 Vol. 45, No. 1. p. 262–265. | | 3. KRISTOFFER R. WEST, MD; ROBERT C. MASON, MS; MIKE SUN, MD, *Nocardia* Spinal Epidural Abscess: 14-year Follow-up. JANUARY 2012 | Volume 35 • Number 1 e128-130. | 4. Ilad Alavi Darazam 1, Masoud Shamaei 1, Mandana Mobarhan 1, Shahin Ghasemi 2, Payam Tabarsi 1, Masoud Motavasseli 1, Davoud Mansouri 1, \*Nocardiosis: Risk Factors, Clinical Characteristics and Outcome. Iranian Red Crescent Medical Journal Iran Red Crescent Med J. 2013;15(5)p436-438. | | 5. V. Lakshmi, C. Sundaram,<sup>\*</sup> A.K. Meena,<sup>\*\*</sup> J.M.K. Murthy<sup>\*\*</sup>. Primary Cutaneous Nocardiosis with Epidural Abscess Caused by *Nocardia brasiliensis* : A Case Report. Neurol India, 2002; 50 : 90-92. | | 6. Saubolle MA, Sussland D. Nocardiosis: a review of clinical and laboratory experience. J Clin Microbiol. 2003; 41(10):4497-4501. | | 7. Epstein S, Holden M, Feldshuh J, Singer JM. Unusual cause of spinal cord compression: nocardiosis. N Y State J Med. 1963; 63:3422- 3427. | | 8. Vander Heiden T, Stahel PF, Clutter S, et al *Nocardia osteomyelitis*: a rare complication after intramedullary nailing of a closed tibial shaft fracture. J Orthop Trauma. 2009; 23(3):232-236. | 9. Goodfellow M, Williams ST. Ecology of actinomycetes. Annu Rev Microbiol. 1983; 37:189-216. | | 10. Satterwhite TK, Wallace RJ Jr. Primary cutaneous nocardiosis. JAMA. 1979; 242(4):333- 336. Chen WC, Wang JL, Wang JT, Chen YC, Chang SC. Spinal epidural abscess due to *Staphylococcus aureus*: clinical manifestations and outcomes. J Microbiol Immunol Infect. 2008; 41(3):215-221. | 11. Davis DP, Wold RM, Patel RJ, et al. The clinical presentation and impact of diagnostic delays on emergency department patients with spinal epidural abscess. J Emerg Med. 2004; 26(3):285-291. | 12. Curry WT Jr, Hoh BL, Amin-Hanjani S, Eskandar EN. Spinal epidural abscess: clinical presentation, management, and outcome. Surg Neurol. 2005; 63 (4):364-371. | | |